CA3204444A1 - Anti-n3pglu amyloid beta antibodies and uses thereof - Google Patents
Anti-n3pglu amyloid beta antibodies and uses thereof Download PDFInfo
- Publication number
- CA3204444A1 CA3204444A1 CA3204444A CA3204444A CA3204444A1 CA 3204444 A1 CA3204444 A1 CA 3204444A1 CA 3204444 A CA3204444 A CA 3204444A CA 3204444 A CA3204444 A CA 3204444A CA 3204444 A1 CA3204444 A1 CA 3204444A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- subject
- weeks
- brain
- doses
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Compounds Of Unknown Constitution (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163135932P | 2021-01-11 | 2021-01-11 | |
| US63/135,932 | 2021-01-11 | ||
| US202163155029P | 2021-03-01 | 2021-03-01 | |
| US63/155,029 | 2021-03-01 | ||
| US202163160380P | 2021-03-12 | 2021-03-12 | |
| US63/160,380 | 2021-03-12 | ||
| US202163192262P | 2021-05-24 | 2021-05-24 | |
| US63/192,262 | 2021-05-24 | ||
| US202163227054P | 2021-07-29 | 2021-07-29 | |
| US63/227,054 | 2021-07-29 | ||
| US202163277298P | 2021-11-09 | 2021-11-09 | |
| US63/277,298 | 2021-11-09 | ||
| US202163284248P | 2021-11-30 | 2021-11-30 | |
| US63/284,248 | 2021-11-30 | ||
| US202263296694P | 2022-01-05 | 2022-01-05 | |
| US63/296,694 | 2022-01-05 | ||
| PCT/US2022/011894 WO2022150735A1 (en) | 2021-01-11 | 2022-01-11 | Anti-n3pglu amyloid beta antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3204444A1 true CA3204444A1 (en) | 2022-07-14 |
Family
ID=80123357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3204444A Pending CA3204444A1 (en) | 2021-01-11 | 2022-01-11 | Anti-n3pglu amyloid beta antibodies and uses thereof |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240010713A1 (https=) |
| EP (1) | EP4274611A1 (https=) |
| JP (2) | JP7676556B2 (https=) |
| KR (2) | KR20260047659A (https=) |
| AU (1) | AU2022206461B2 (https=) |
| CA (1) | CA3204444A1 (https=) |
| CL (1) | CL2023001992A1 (https=) |
| CO (1) | CO2023009089A2 (https=) |
| EC (1) | ECSP23051813A (https=) |
| IL (1) | IL304072A (https=) |
| MX (1) | MX2023008196A (https=) |
| PE (1) | PE20231748A1 (https=) |
| TW (1) | TWI843040B (https=) |
| WO (1) | WO2022150735A1 (https=) |
| ZA (1) | ZA202306180B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022307687A1 (en) * | 2021-07-09 | 2024-01-04 | Eisai R&D Management Co., Ltd. | Biomarkers for alzheimer's disease treatment |
| WO2023039107A2 (en) | 2021-09-09 | 2023-03-16 | Alzpath, Inc. | Phospho-tau antibodies and methods of use |
| CA3243602A1 (en) * | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease |
| KR20250107906A (ko) * | 2022-11-17 | 2025-07-14 | 일라이 릴리 앤드 캄파니 | 항-N3pGlu 아밀로이드 베타 항체, 그의 용량 및 용도 |
| KR20250173598A (ko) * | 2023-03-16 | 2025-12-10 | 알즈패스, 인크. | 신경퇴행성 질환의 진단 및 치료 방법 |
| WO2025231343A1 (en) * | 2024-05-03 | 2025-11-06 | Therini Bio, Inc. | Doses of antibodies which bind human fibrin yc or fibrinogen yc domain for neurodegenerative diseases |
| WO2025240435A1 (en) * | 2024-05-14 | 2025-11-20 | Othair Prothena Limited | Methods of treating neurological disorders with anti-abeta antibodies |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1257584T1 (de) | 2000-02-24 | 2003-05-28 | Lilly Co Eli | Humanisierte antikörper, die amyloid beta peptid demarkieren |
| PT1944040E (pt) | 2001-08-17 | 2012-10-31 | Univ Washington | Método de avaliação para a doença de alzheimer |
| SI1720909T1 (sl) | 2004-02-23 | 2012-01-31 | Lilly Co Eli | Anti-abeta protitelo |
| WO2010009987A2 (en) | 2008-07-21 | 2010-01-28 | Probiodrug Ag | Diagnostic antibody assay |
| WO2011151076A2 (en) | 2010-06-04 | 2011-12-08 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS |
| PL3042917T3 (pl) | 2010-08-12 | 2018-07-31 | Eli Lilly And Company | Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie |
| WO2012021475A2 (en) * | 2010-08-12 | 2012-02-16 | Eli Lilly And Company | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| US9499610B2 (en) | 2011-04-08 | 2016-11-22 | H. Lundbeck A/S | Antibodies specific to pyroglutamated Aβ |
| JOP20170004B1 (ar) | 2016-01-15 | 2022-09-15 | Lilly Co Eli | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته |
| TWI798751B (zh) * | 2016-07-01 | 2023-04-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| TWI789644B (zh) | 2017-04-20 | 2023-01-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| CN107289872A (zh) | 2017-06-28 | 2017-10-24 | 京东方科技集团股份有限公司 | 测高装置 |
| KR102905634B1 (ko) | 2019-05-31 | 2025-12-30 | 일라이 릴리 앤드 캄파니 | 인간 타우를 표적화하는 화합물 및 방법 |
-
2022
- 2022-01-10 TW TW111101008A patent/TWI843040B/zh active
- 2022-01-11 IL IL304072A patent/IL304072A/en unknown
- 2022-01-11 KR KR1020267008447A patent/KR20260047659A/ko active Pending
- 2022-01-11 AU AU2022206461A patent/AU2022206461B2/en active Active
- 2022-01-11 CA CA3204444A patent/CA3204444A1/en active Pending
- 2022-01-11 WO PCT/US2022/011894 patent/WO2022150735A1/en not_active Ceased
- 2022-01-11 JP JP2023541749A patent/JP7676556B2/ja active Active
- 2022-01-11 US US18/260,125 patent/US20240010713A1/en active Pending
- 2022-01-11 EP EP22701816.5A patent/EP4274611A1/en active Pending
- 2022-01-11 KR KR1020237027055A patent/KR102942744B1/ko active Active
- 2022-01-11 MX MX2023008196A patent/MX2023008196A/es unknown
- 2022-01-11 PE PE2023002030A patent/PE20231748A1/es unknown
-
2023
- 2023-06-12 ZA ZA2023/06180A patent/ZA202306180B/en unknown
- 2023-07-06 CL CL2023001992A patent/CL2023001992A1/es unknown
- 2023-07-07 CO CONC2023/0009089A patent/CO2023009089A2/es unknown
- 2023-07-10 EC ECSENADI202351813A patent/ECSP23051813A/es unknown
-
2025
- 2025-04-30 JP JP2025075147A patent/JP2025131566A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TWI843040B (zh) | 2024-05-21 |
| AU2022206461A1 (en) | 2023-06-29 |
| ZA202306180B (en) | 2025-02-26 |
| PE20231748A1 (es) | 2023-11-06 |
| TW202243690A (zh) | 2022-11-16 |
| IL304072A (en) | 2023-08-01 |
| MX2023008196A (es) | 2023-07-18 |
| KR20260047659A (ko) | 2026-04-08 |
| WO2022150735A1 (en) | 2022-07-14 |
| KR20230130695A (ko) | 2023-09-12 |
| EP4274611A1 (en) | 2023-11-15 |
| CO2023009089A2 (es) | 2023-09-29 |
| KR102942744B1 (ko) | 2026-03-23 |
| JP7676556B2 (ja) | 2025-05-14 |
| CL2023001992A1 (es) | 2024-02-02 |
| US20240010713A1 (en) | 2024-01-11 |
| JP2025131566A (ja) | 2025-09-09 |
| JP2024503025A (ja) | 2024-01-24 |
| AU2022206461B2 (en) | 2026-02-05 |
| ECSP23051813A (es) | 2023-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022206461B2 (en) | Anti-n3pglu amyloid beta antibodies and uses thereof | |
| AU2022232936B2 (en) | Anti-amyloid beta antibodies and uses thereof | |
| TW202317192A (zh) | 用於阿茲海默氏症治療的生物標記物 | |
| EP3464350A1 (en) | Methods for treating alzheimer's disease | |
| US20250377367A1 (en) | Methods of treatment using p-tau181 level | |
| TW202430554A (zh) | 使用ｔａｕ ＰＥＴ水平之治療方法 | |
| EA052116B1 (ru) | Антитела к бета-амилоидному пептиду n3pglu и варианты их применения | |
| CN116916957A (zh) | 抗N3pGlu淀粉样蛋白β抗体及其用途 | |
| CN116981690A (zh) | 抗-淀粉样蛋白β抗体及其用途 | |
| WO2026055601A1 (en) | METHOD OF TREATING ALZHEIMER'S DISEASE USING ANTI-N3pGlu AMYLOID BETA ANTIBODIES | |
| WO2026075947A1 (en) | Dosing regimens for early alzheimer's disease | |
| WO2022251048A1 (en) | Anti-amyloid beta antibodies and uses thereof | |
| KR20260038283A (ko) | 항미생물 펩티드 | |
| NZ788486A (en) | Methods for treating Alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230901 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240906 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241224 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241224 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241224 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250106 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250211 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250528 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250528 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251008 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251217 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251217 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260206 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260211 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260212 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260212 |